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Abstract: The term cytoprotection pioneered by Robert and colleagues has been introduced to describe the remarkable ability of 
endogenous and exogenous prostaglandins (PGs) to prevent acute gastric hemorrhagic lesions induced by noxious stimuli such as 
ethanol, bile acids, hiperosmolar solutions and nonsteroidal anti-inflammatory agents such as aspirin. Since that time many factors were 
implicated to possess gastroprotective properties such as growth factors including epidermal growth factor (EGF) and transforming factor 
alpha (TGF), vasodilatory mediators such as nitric oxide (NO) and calcitonin gene related peptide (CGRP) as well as appetite gut 
hormones including gastrin and cholecystokinin (CCK), leptin and recently ghrelin. This protective action of gut peptides has been 
attributed to the release of PG but question remains whether another peptide angiotensin, the classic component of the systemic and local 
renin-angiotensin system (RAS) could be involved in the mechanism of gastric integrity and gastroprotection. After renin stimulation, the 
circulating angiotensin I is converted to angiotensin II (ANG II) by the activity of the Angiotensin Converting Enzyme (ACE). The ANG 
II acting via its binding to two major receptor subtypes the ANG type 1 (AT1) and type 2 (AT2) has been shown be activated during 
stress and to contribute to the pathogenesis of cold stress- and ischemia-reperfusion-induced gastric lesions. All bioactive angiotensin 
peptides can be generated not only in systemic circulation, but also locally in several tissues and organs. Recently the new functional 
components of RAS, such as Ang-(1-7), Ang IV, Ang-(1-12) and novel pathways ACE2 have been described suggesting the 
gastroprotective role for the novel ANG II metabolite, Ang-(1-7). The fact that Ang-(1-7) is produced in excessive amounts in the gastric 
mucosa of rodents and that pretreatment by Ang-(1-7) exhibits a potent gastroprotective activity against the gastric lesions induced by 
cold-restraint stress suggests that this and possibly other vasoactive metabolites of ANG II pathway could be involved in the mechanism 
of gastric integrity and gastroprotection. This review summarizes the novel gastroprotective factors and mechanisms associated with 
metabolic fate of systemic and local RAS activation with major focus to recent advancement in the angiotensin pathways in the gut 
integrity.  
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1. GASTRIC MUCOSAL INTEGRITY SYSTEM, CYTOPRO-
TECTION AND ADAPTIVE CYTOPROTECTION 
Previous studies have documented that the gastric mucosa of 
both humans and animals can resist the damage induced by the 
ingestion of strong topical irritants and ulcerogens [1-3]. This is 
accomplished by balancing the damaging properties of the 
corrosive compounds and various stressors with the strengthening 
effects of the particular lines on the mucosal defense system, thus 
preventing mucosa injury. The major homeostatic mechanisms 
involved in the gastric mucosal defense system are the undisturbed 
gastric mucosal blood flow, the secretion of protective mucus and 
bicarbonate secretion, the hydrophobic nature of mucosal lining, the 
generation of protective prostaglandins and the mucosal sulfhydryls 
within gastric mucosa as well as the vasodilatatory activity of 
sensory neuropeptides released at the sensory afferent nerve 
endings. The research that primarily influenced our understanding 
of the field of gastric mucosal barrier was originally pioneered by 
C. Code and H. Davenport [1], and was derived from animal studies 
performed by Andre Robert and his colleagues [2] who proposed 
the term "cytoprotection". This team described for the first time the 
unusual features of prostaglandins (PG), the major products of 
arachidonate metabolism, when given in a non-antisecretory dose, 
capable of limiting or even completely prevents the gastric mucosal 
injury induced by strong irritants and corrosive agents [2]. This 
discovery was at that time a real breakthrough in the field of 
gastroenterology and shifted the focus of the scientific research of 
many groups worldwide to search for the compounds that were 
effective in the prevention of gastric damage independently from 
the inhibitory effect on gastric acid secretion, which was 
conventionally believed to play a role in the pathogenesis of peptic 
ulcer disease. Interestingly, PG applied topically or systemically at  
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small non-antisecretory concentrations were convincingly effective 
in the protection of the gastric mucosa exposed to the obnoxious 
action of not only necrotizing substances such as ethanol, but also 
hiperosmolar solutions, strong acids (e.g. 0.6 N HCl), bases (e.g. 
0.2 N NaOH), concentrated bile, aspirin and even the direct burning 
effects of boiling water [2-4]. Further detailed studies on the 
mechanism of action of PG provided the clue for their phenomenal 
activity by demonstrating that these arachidonate metabolites can 
increase the gastric microcirculation, stimulate the gastric mucus 
and bicarbonate secretions, enhance the level of mucosal sulfhydryl 
compounds and increase the mucosal hydrophobicity [5]. 
Moreover, PG can directly protect freshly isolated gastric mucosal 
cells and whole isolated rat and human gastric glands in vitro 
against gastric injury induced by alcohol or indomethacin, therefore 
suggesting PG-induced protection independent from vascular, 
neural and endocrine factors [6-8]. Soon it became clearly evident 
that certain growth factors, especially EGF, TGF and bFGF, could 
be also considered as gastroprotective because they were capable of 
reducing aspirin-induced gastric ulcerations under conditions where 
biosynthesis of endogenous PG was completely inhibited by the 
administration of this NSAID [9]. 
One of the important forms of cytoprotection is "adaptive 
cytoprotection", the term that was originally introduced by Robert 
and his associates (3) to describe the protective activity of 
endogenous PG generated within the gastric mucosa by mild topical 
irritants such as 20 % ethanol, 5 mM NaCl or 5 mM taurocholate in 
the presence of strong irritants such as 100 % ethanol, 25 % NaCl 
or 80 mM taurocholate, known to produce acute hemorrhagic 
gastric lesions [10]. The concept of cytoprotection pioneered by 
Robert's experimentation was further extended by the observation 
that mild irritants afforded a cross-protective response, e.g. 5% 
NaCl was effective in the attenuation of damage induced not only 
by necrotizing 25 % NaCl but also by 100% ethanol, while 20% 
ethanol prevented the damage caused by 100% ethanol or 25% 
NaCl [11]. Moreover, using a bioassay technique to measure the 
generation of prostacyclin (PGI2) and PGE2 in the gastric mucosa, 
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our research as well as others revealed that the pretreatment of 
gastric mucosa with mild irritant resulted in an enhancement of the 
mucosal generation of PGI2 and PGE2, thus providing direct 
evidence for the involvement of endogenous PG in the mechanism 
of adaptive cytoprotection [11-13]. Thus, it was proposed that 
endogenous PG are involved in protecting the mucosa against the 
mild irritating damage induced in the stomach by strong irritants 
applied in higher concentrations, as they protect mainly the 
proliferative zone of the gastric glands [14,15]. Some other peptides 
such as cholecystokinin, gastrin, leptin and ghrelin were shown 
later on to exert gastroprotection [16-21], thus confirming that the 
ability to protect the gastric lining could not be entirely attributed to 
PG as initially assumed but might be shared by various peptides and 
compounds with a non-peptide origin.  
2. FUNCTIONAL COMPONENTS AND SIGNIFICANCE OF 
RENIN-ANGIOTENSIN SYSTEM (RAS) 
Since the first identification of renin by Tigerstedt and 
Bergmann in 1898 [22], the renin-angiotensin system (RAS) has 
been extensively studied. The current view of the system is 
characterized by an increased complexity, as evidenced by the 
discovery of new functional components and pathways of the RAS. 
The octapeptide ANG II was discovered as a circulating pro-
hypertensive principle of renal origin [23]. The activation of RAS 
remains as a sequential step to the activation of the precursor 
molecule angiotensinogen. This protein, predominantly synthesized 
by the liver, is released to the circulation and become cleaved by 
renin, a circulating enzyme of renal origin and the rate-limiting 
factor for the system. Due to the action of renin, angiotensin I, an 
inactive decapeptide is formed. The circulating angiotensin I is then 
converted to its active principle, angiotensin II (ANG II) by a 
peptidase, the Angiotensin Converting Enzyme (ACE), which is 
predominantly located on the surface of lung endothelial cells. 
Originally, the circulating ANG II was considered the main effector 
acting via its binding to two major receptor subtypes the ANG type 
1 (AT1) and type 2 (AT2) involved in the regulation of blood 
pressure and body fluid control [23,24]. The chemical structure of 
major RAS peptides Ang I and ANG II as well as the Ang-(1-7), 
the vasoactive metabolite of ANG II, are presented in Fig. (1).  
ANG II, the major effector hormone of RAS, modulates 
cardiovascular function by inducing vasoconstriction, renal salt and 
water retention and facilitating sympathetic transmission [25]. In 
addition, ANG II can induce hypertrophy and/or hyperplasia in the 
arteries of resistance and cardiomyocytes, thus playing a 
pathophysiological role in the development and maintenance of 
hypertension [26]. These effects on the cardiovascular system are 
clearly mediated by the activation of angiotensin AT1 receptors 
[26]. Both AT1 and AT2 receptor subtypes may play a divergent 
role, because the AT1 receptor is involved in the cell proliferation 
and the production of cytokines, while the AT2 receptor was 
reported to regulate the control of blood pressure and to cause the 
inhibition of cell proliferation, thus contributing to neointimal 
formation after vascular injury [27]. Some ANG II responses, 
including NO release and collagen synthesis are mediated by both 
AT1 and AT2 receptors [28,29]. Both AT1 and AT2 receptor 
antagonists showed a satisfactory efficacy and safety allowed for 
widespread use in the treatment of hypertension. Furthermore their 
anti-inflammatory and vascular protective effects contribute to 
reduce renal and cardiovascular failure [30,31]. Blockade of the 
AT1 receptors in humans is also neuroprotective, reducing the 
incidence of stroke, improving cognition and decreasing the 
progression of Alzheimer’s disease [32], and could be useful in 
lung disorders such as chronic obstructive pulmonary diseases 
(COPD) and acute respiratory distress syndrome [33].  
3. ROLE OF RENIN-ANGIOTENSIN (RAS) IN THE 
MECHANISM OF GASTRIC MUCOSAL INTEGRITY 
Numerous studies have shown that the RAS exerts its endocrine 
effect on hemodynamic regulation and body fluid homeostasis [34] 
but less is known about its regulatory impact of the tissue based 
local RAS, especially in the GI-tract. The existence of local RAS 
has been demonstrated in a number of organs e.g. brain [32], and 
gastrointestinal organs including the pancreas, esophagus and colon 
[35,36].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Chemical structure of major components of RAS system angiotensin I and angiotensin II and the active metabolite of angiotensin II, angiotensin-(1-
7).  
Angiotensin I Angiotensin II  
Angiotensin-(1-7)
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The involvement of RAS in the mechanism of gastric integrity 
and gastroprotection still should be elucidated, but its significance 
was documented in the pathogenesis of stress, indomethacin and 
ischemia reperfusion induced gastric damage [36-41]. It is well 
known that stress induces acute gastric mucosal lesions by complex 
psychological factors influencing individual vulnerability, 
stimulation of specific brain pathways regulating autonomic 
function, decreased blood flow to the mucosa, an increasing 
muscular contractility and smooth muscle motility, mast cell 
degranulation, leukocyte activation, and increased free radical 
generation resulting in increased lipid peroxidation [42,43]. Cold-
restraint stress is commonly used and a clinically relevant 
experimental model for acute gastric damage [44]. A sudden 
reduction in blood flow to the gastric mucosa and increased free 
radical formation plays a fundamental role in the production of 
lesions and erosions that may predispose to ulcer formation [43]. 
The maintenance of gastric blood flow is important to protect the 
mucosa from endogenous and exogenous damage factors. ANG II 
is activated during stress and that the level of this hormone 
dramatically increases during stress in plasma and peripheral tissues 
including the stomach [36]. ANG II contributes to the pathogenesis 
of inflammation induced by various stressors such as ischemia-
reperfusion and cold stress resulting in acute lesions in the gastric 
mucosa of rodents [39,40,45]. ANG II elicits a cellular response 
through several molecular signaling pathways, such as calcium 
mobilization, reactive oxygen metabolite generation, and activation 
of protein kinase and nuclear transcription factors including nuclear 
factor B (NFB) [46-48]. On the other hand, this peptide might 
contribute to the mucosal defense mechanism via activation of the 
vascular tone in the arteries of resistance. However, ANG II was 
shown to not only regulate vascular tone in the arteries of resistance 
[24] and in the brain tissue [49] but also constricts the gastric 
vasculature through AT1 receptor stimulation [26]. In addition, 
ANG II was shown to generate an excessive amount of reactive 
oxygen species followed by cellular damage and inflammation and 
to cross-talk with other inflammatory second messengers such as 
nitric oxide (NO), and PGs through NFB-dependent mechanism 
[48,50,51]. 
The inhibition of ANG II AT1 receptors with peripheral and 
central receptor antagonists [49] prevents the sympathoadrenal and 
hypothalamic-pituitary-adrenal response to isolation stress and 
protects the brain from injury by reducing the cerebral blood flow 
during a stroke [45,52]. The question remains whether antagonism 
of the AT1 receptors could attenuate the incidence of cold stress-
induced gastric lesions and whether AT1 receptor blockade could 
be of therapeutic usefulness in this stress-related disorder. To 
address this question, a widely used strain of spontaneously 
hypertensive rats (SHR) characterized by increased 
sympathoadrenal reactivity to stress was employed because of the 
well-known association between stress and cardiovascular disease 
[36]. In this study, the SHR rats were pretreated with an AT1 
receptor blocker before cold-restraint stress. It was found that the 
AT1 antagonists exhibited the protection against stress-induced 
gastric lesions due to the suppression of the stress-induced 
hormonal axis and sympathoadrenal response, the attenuation of the 
vasoconstrictor effects of ANG II in the gastric microcirculation, 
thereby causing an inhibition of mucosal inflammation [36,46,48]. 
There is a growing body of evidence that the components of the 
renin-angiotensin system (RAS) are present in many organs 
including the stomach [53], and pancreatic islets [54]. ANG II is a 
well-known oxidative stress inducer which increases the generation 
of superoxide anion, hydrogen peroxide and hydroxyl radicals by 
activating the NADPH oxidase enzyme [55,56]. This action is 
associated with the activation of the inflammatory cascades with 
increased production of the proinflammatory cytokine, TNF-, 
which is involved in the pathogenesis of gastric mucosal injury 
[36].  
Since indomethacin-induced acute gastric ulceration is 
associated with an increased production of TNF- in the gastric 
mucosa [57,58], the treatment with telmisartan, the AT1 receptor 
antagonist, appeared as a good alternative in protection against 
indomethacin damage [26]. Other mechanisms independent of AT1 
receptor blockade are responsible for the antioxidant and anti-
inflammatory activities of telmisartan, which acts as a partial 
agonist at the nuclear peroxisome proliferator-activated receptor-
gamma (PPAR) [59]. Activation of this PPAR receptor system 
induces catalase gene expression and NFB, and therefore 
combating oxidative stress and down-regulating most of the 
proinflammatory responses [60,61]. The study by Morsy et al. [62] 
documented that rosiglitazone, an agonist of PPAR receptors 
significantly protected against indomethacin-induced gastric ulcer 
in type 2 diabetic rats. The inhibitory effects of telmisartan on 
gastric lesions could be in part, attributed to its PPAR agonist 
activity and the inhibitory action of this AT1 receptor antagonist on 
the caspase-3 activation, a proapoptotic system required for the 
execution of cell apoptosis. It is likely that the antiapoptotic activity 
of telmisartan depends upon the reduced generation of reactive 
oxygen species, the inhibition of TNF- and an increase in NO 
production as originally indicated [63,64] but seems to be 
independent from the generation of PGE2 which is suppressed by 
indomethacin.  
The interaction of RAS with the physiology and pathology of 
the gut has not been extensively studied with respect to 
Helicobacter pylori (H.pylori), the major pathogen responsible for 
gastric disorders such as gastritis, ulcer formation and sometimes 
gastric cancer. Hallesrund et al. [65,66] reported that AT1 and AT2 
receptor subtypes are expressed in the gastric wall of Mongolian 
gerbils and in human gastric mucosa. The subpopulation of 
endocrine cells within the antral gastric mucosa showed a distinct 
immunostaining for AT1 receptor [66]. Interestingly, the AT1 
receptors were abundant in H.pylori-infected gastric mucosa of 
Mongolian gerbils and associated with tissue infiltration by 
neutrophils expressing this receptor [66]. This was in keeping with 
the previous observations that local RAS is closely associated with 
inflammation [28]. Recent investigations attempted to look for the 
expression of AT1 and AT2 receptors as well as the ANG II 
generating enzymes, namely renin, ACE and neprilysin (NEP) 
[65,66]. It now becomes clear that AT1R and AT2R receptors of 
principal action ANG II, one of major RAS component, are 
localized to both gland structures and the surface epithelium, as 
well to mesenchymal cells and vessels in the lamina propria [66]. 
Moreover, the human gastric mucosa expresses the 
proangiotensinogen, renin and ACE suggesting the involvement of 
RAS in the mechanism of gastric integrity [66]. Similarly as in 
gerbils, the endocrine cells in the human antral gastric mucosa 
exhibited the expression of AT1 receptors, and this expression was 
further potentiated in H.pylori-infected gastric mucosa, with the 
latter effect being correlated to an increase in neutrophil-infiltrating 
inflamed gastric mucosa [66]. It is of interest that the rise in the 
expression of AT1 receptors does not seem to correlate with the 
number of lymphocytes. This observation was in accordance with 
the report of Rasini et al. [67] who found that neutrophils in the 
human blood have the highest AT1 receptor expression among all 
population of white blood cells investigated. The expression of AT1 
receptor could be linked to the increased production of reactive 
oxygen metabolites (ROM) since Mongolian gerbils infected with 
H.pylori revealed an increase in the hydrogen peroxide [68]. 
Constant ROM generated locally in the gastric mucosa in response 
H.pylori and the release of its bacterial cytotoxins encoding for 
CagA and VacA might explain the link between gastritis, the 
gastroduodenal ulcerations and in some cases cancer development 
in H.pylori-infected individuals [69]. This suggests that the 
activation of local RAS, the enhanced AT1 receptors and ROM 
generation affecting gastric microcirculation, which may contribute 
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to H.pylori-induced tissue damage and a DNA mutation that 
predisposes the gastric mucosa to gastric adenocarcinoma [70].  
4. ANG-(1-7) AS ONE OF THE MAJOR VASODILATORY 
AND PROTECTIVE RAS COMPONENTS IN THE GUT 
Active metabolites of local RAS exhibit a profound 
physiological effects on the vasculature and therefore could be 
considered an important component of the gastrointestinal defense 
system. Using the mesenteric arterial bed (MAB) of normotensive 
rats, Soares de Moura et al. [71] have demonstrated that ANG II 
has no vasoconstrictor effect on the resting perfusion pressure, but 
induces an endothelium-derived relaxing factor (EDRF)-dependent 
effect when these vessels are preconstricted with noradrenalin 
(NA). In addition, they provided evidence that this effect seems to 
be modulated by an interaction with ANG II, bradykinin (BK) and 
Ang-(1–7) receptors [71]. Recent studies in spontaneously 
hypertensive rats (SHR) have demonstrated that the contraction 
induced by ANG II in the isolated aorta and mesenteric arteries is 
reversed with vasodilatation after chronic treatment with AT1 
receptor antagonists [72,73]. The AT2 receptor-mediated 
vasodilator response could also significantly contribute to the 
observed beneficial hemodynamic effects of the AT1 receptor 
blockade. These observations pointed out the role of active 
metabolites of ANG II such as Ang-(1–7), which is a potent 
vasodilator compound [74,75] and an endogenous ligand of the 
specific Mas receptor [76]. The Mas oncogene is a G protein-
coupled receptor which binds the ANG II metabolite, Ang-(1-7) 
[76]. Recent evidence indicates that the Mas receptor when 
activated by binding Ang-(1-7) opposes many of the effects of 
ANG II activated angiotensin receptor [76]. Ang-(1-7) could be 
involved in the mechanism of action of ANG II in rat MAB because 
both Ang-(1–7) and ANG II-induced a similar vasodilatatory 
response in the MAB. At a concentration that reduced the 
vasodilator effect of Ang-(1–7), the A779, a putative Ang-(1–7) 
antagonist, also reduced the vasodilator effect of ANG II, 
suggesting a contribution of Ang-(1–7) to the vasodilator effect of 
ANG II. Further proof of vasodilatory action of Ang-(1-7) was 
delivered by Oliveira et al. [77] who demonstrated that the Ang-(1-
7) potentiation of bradykinin-induced vasodilatation in rat 
mesenteric vessels is abolished by NO-synthase inhibitor, L-
NAME. 
These observations significantly changed our understanding of 
the contribution of RAS to the functioning of particular metabolites 
in peripheral organs emphasizing the protective role of some of the 
active metabolites of RAS, in particular ANG II. This notion is 
based on the fact that the new functional components of RAS, such 
as Ang-(1-7), Ang IV, Ang-(1-12) and novel pathways ACE2 have 
been described [78,81] but their role in GI-tract should be 
investigated. An important observation is that all bioactive 
angiotensin peptides can be generated not only in systemic 
circulation, but also locally in several tissues and organs. These 
peptides acting via autocrine and/or paracrine manner have been 
described in the kidney, heart, liver, pancreas, adrenal gland, brain, 
ovaries and testes [82-84]. Indeed, the pretreatment by Ang-(1-7) 
exhibited a potent gastroprotective activity against the gastric 
lesions induced by cold-restraint stress in rats [85] and this effect 
was accompanied by the marked increase in the gastric blood flow 
that counteracted the fall in flow observed in animals not pretreated 
with this vasoactive metabolite of ANG II. Moreover, the plasma 
cytokine IL-1 and TNF- was significantly increased in stressed 
animals and this effect was ameliorated in rats pretreated with Ang-
(1-7) (Fig. 2). In contrast, ANG II administered under the same 
experimental conditions to stressed rats, exacerbated the cold-
restraint gastric lesions and produced a further fall in the gastric 
blood flow and the significant elevation of plasma IL-1 and TNF-
 levels as compared to the respective controls (Fig. 2). This 
finding clearly indicates that endogenous generation of Ang-(1-7) 
could act as the important protector and vasodilator of the gastric 
mucosa and further studies should confirm the role of this novel 
factor and its efficacy in the mechanism of ulcer healing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The effect of pretreatment with Ang-(1-7) and ANG II on the 
plasma proinflammatory cytokine IL-1 and TNF- levels during cold 
stress-induced ulcerogenesis in rats. Ang-(1-7) shows remarkable 
attenuation of plasma cytokines while the pretreatment with ANG II 
significantly enhanced the level of IL- and TNF- in rats exposed to cold 
stress. Results are mean±SE of 6-8 rats per each experimental group. 
Asterisk indicates a significant increase (p<0.05) from intact animals. 
Asterisk and cross indicate a significant increase (p<0.05) above the values 
obtained in rats pretreated with ANG II. Single cross indicates a significant 
change (p<0.05) from the values obtained in vehicle-control rats and those 
pretreated with ANG II.  
ANG II has been implicated in the pathogenesis of gastric 
lesions [86-88] but the recent evidence indicated that both, ACE 
and ACE2 involved in Ang I and ANG II conversion pathway are 
expressed in the gastric mucosa [89,90]. Recently, Olszanecki and 
colleagues [91] made an important contribution to the field of 
angiotensin research. Using liquid chromatography and electrospray 
ionization - mass spectrometry (LC-ESI-MS), they developed an 
accurate, reproducible and comprehensive method of quantitation 
of formation of angiotensin peptides in an organ bath of gastric 
mucosal tissue fragments exposed to exogenous ANG I [90,91] 
(Fig. 3). This method allowed them to assess the metabolism of 
Ang I in an organ bath of rat stomach walls [90]. They identified 
Ang-(1-7) as the main product of Ang I conversion in the rat 
stomach wall despite that there were apparent discrepancies 
concerning the Ang I conversion pathways in the stomach, aorta 
and renal artery [91]. The expression of mRNA for ACE and ACE2 
in the stomach and aorta and the overall rate of generation of Ang I 
metabolites were much lower in the stomach wall but the 
prevalence of ANG II formation was evidently higher in the aorta, 
but that of Ang-(1-7) was evidently superior in the gastric mucosa 
comparing other tissues (Fig. 4). They referred this apparent 
difference between particular angiotensins Ang I and ANG II to 
posttranscriptional regulation of enzymes involved in angiotensin 
metabolism in various organs including the stomach and vascular 
bed [91] but to confirm that hypothesis detailed studies at the 
protein level are needed. 
Ang-(1-7) could directly originate from Ang I via NEP activity 
detected in the gastric mucosa as well as indirectly via ANG II 
(sequential action of ACE then ACE2) or via the formation of Ang-
(1-9) due to the combined activity of ACE2 and later on ACE. 
Study by Olszanecki et al. [91] revealed that the gastric formation 
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Fig. (3). Chromatogram analysis of angiotensin I, II. III, IV, 1-9, 1-7 and 1-5 standards separated originally by HPLC method followed by Liquid 
chromatography - Electrospray ionization - Mass spectrometry (LC-ESI-MS) (adapted with permission from Bujak-Gizycka et al. Journal of Physiology and 
Pharmacology 2007, 58, 3, 529-540).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Proposed scheme of the existence and contribution of systemic and local renin-angiotensin system (RAS) in the gastric mucosa of the stomach 
exposed to noxious stimuli such as stress, ethanol, aspirin or ischemia. Both systemic and local RAS activation starts from Angiotensin I that is formed from 
angiotensinogen via the stimulation of renin activity. Angiotensin I is converted into ANG II due to the action of ACE. ANG II give rise to its major metabolite 
Ang-(1-7) which acts on specific Mas receptor. Injury to the gastric mucosa may trigger the local RAS in the microcirculation of the gastric wall and in the 
epithelial cells. ANG II activates AT1 and AT2 receptors and contributes to the injury induced by various systemic and topical ulcerogens. In contrast, the 
active metabolite of ANG II, Ang-(1-7) exhibits a potent gastroprotective action mediated by NO and possibly by endogenous PG system. Ang-(1-7) was 
recently shown to inhibit the generation of reactive oxygen metabolites and activate the free radical scavenging enzyme, catalase.  
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of Ang-(1-7) seems to not depend on the activity of ACE and NEP 
since the generation of Ang II was completely inhibited by 
perindoprilat.  
5. SUMMARY 
Prostaglandins were originally considered as a pivotal 
cytoprotective agents exerting also a profound influence on the 
process of ulcer healing [92]. More recently other physiological 
mediators such as salivary growth factors (EGF) and the activity of 
vagal innervation [93] as well as the vasoreactive compounds (NO 
and hydrogen sulfide) were implicated in the mechanism of 
cytoprotection and the process of gastroduodenal ulcer healing. 
This review sheds some light on the importance of local RAS and 
Ang-(1-7), acting via the MAS receptor to directly antagonize many 
actions of ANG II [76,94], thus contributing to the mechanism of 
gastric integrity and gastroprotection. According to this new 
concept, RAS can be considered as a dual function system in which 
the vasoconstrictor and damaging or vasodilatatory and 
gastroprotective actions are primarily driven by the balance 
between ACE/Ang II/AT1 receptor and ACE2/Ang-(1-7)/MAS 
receptor pathways, respectively [94,95] (Fig. 4). It has been 
recently suggested that part of the beneficial effects of drugs like 
ACE inhibitors or AT1 receptor blockers may depend on shifting 
the balance toward ACE-2/Ang-(1-7)/MAS axis [95,96]. This is in 
keeping with previous observations that ACE inhibitors and AT1 
receptor blockers may prevent stress-induced gastric injury [31] 
suggesting that these protective and hyperemic effects could be 
mediated, at least in part, by Ang-(1-7) as the main beneficial 
product of Ang I conversion within the gastric mucosa (Fig. 4). The 
role of particular components of RAS in more chronic models of 
experimental gastric ulcer as well as studies on Ang-(1-7) in the 
human pathophysiology of peptic ulcer disease warrants further 
investigation.  
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